Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics



Anti-Cancer Agents in Medicinal Chemistry, 3(6): 411-420.

Author(s): Jose Portugal.

Affiliation: Departamento de Biologia Molecular y Celular, Instituto de Biologia Molecular de Barcelona, CSIC,Jordi Girona, 18-26, 08034 Barcelona, Spain.

Abstract

Chartreusin and elsamicin A are structurally related antibiotics that bind to GCrich tracts in DNA, with a clear preference for B-DNA over Z-DNA. They inhibit RNA synthesis and cause single-strand scission of DNA via the formation of free radicals. Elsamicin A can also be regarded as the most potent inhibitor of topoisomerase II reported so far. It can inhibit the formation of several DNA-protein complexes. Elsamicin A binding to the P1 and P2 promoter regions of the c-myc oncogene inhibits the binding of the Sp1 transcription factor, thus inhibiting transcription. Despite the pharmacological interest in chartreusin, elsamicin A and their derivatives, there is no experimental data on the structure of their complexes with DNA. This shortcoming has been partially solved by a theoretical approach, which provided some details about the DNAelsamicin A interaction, and the thermodynamic characterization of the binding of chartreusin and elsamicin A to DNA. Elsamicin A but not chartreusin is being developed clinically as an anti-cancer agent. IST-622 (6-O-(3- ethoxypropylonyl)-3,4-O-exo-benzylidene-chartreusin), a novel semi-synthetic derivative of chartreusin, which has shown a promising anti-cancer activity in a phase II study, appears to be a pro-drug with a more suitable pharmacokinetic profile than chartreusin.

Keywords:

dna-binding drugs, chartreusin, elsamicin a, intercalation.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 3
Issue Number: 6
First Page: 411
Last Page: 420
Page Count: 10
DOI: 10.2174/1568011033482215
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science